Actinium Pharmaceuticals (NYSE:ATNM) Stock Rating Reaffirmed as “Buy” by HC Wainwright

Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $4.00 price objective on the stock. HC Wainwright‘s price objective points to a potential upside of 168.46% from the company’s previous close.

Actinium Pharmaceuticals Trading Down 9.1%

Shares of ATNM stock opened at $1.49 on Tuesday. Actinium Pharmaceuticals has a 12 month low of $0.74 and a 12 month high of $1.72. The stock has a market cap of $46.85 million, a P/E ratio of -1.07 and a beta of 0.27. The company has a 50 day simple moving average of $1.29 and a two-hundred day simple moving average of $1.13.

Institutional Trading of Actinium Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Compass Financial Management LLC bought a new position in shares of Actinium Pharmaceuticals in the second quarter worth about $588,000. BlackRock Inc. purchased a new position in shares of Actinium Pharmaceuticals during the 2nd quarter valued at about $388,000. Finally, Renaissance Technologies LLC grew its stake in shares of Actinium Pharmaceuticals by 20.7% during the 1st quarter. Renaissance Technologies LLC now owns 471,600 shares of the company’s stock valued at $469,000 after acquiring an additional 80,816 shares during the period. Hedge funds and other institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

(Get Free Report)

Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for patients with cancer, particularly blood cancers. Its approach combines cancer-targeting antibodies with radioactive isotopes intended to deliver radiation to specific cells. The company’s investigational programs include Iomab-B (apamistamab), an iodine-131-labeled antibody targeting CD45, developed as a conditioning treatment before a bone marrow transplant for certain patients with acute myeloid leukemia.

Read More

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.